Related Experiment Videos
Advanced therapy for juvenile arthritis.
Kevin J Murray1, Daniel J Lovell
1Paediatric Rheumatology Unit, Great Ormond St Hospital for Children, London WC1N 3JH, UK.
Best Practice & Research. Clinical Rheumatology
|October 22, 2002
Summary
Recent advancements in juvenile idiopathic arthritis (JIA) management, including new drugs and biological agents, have greatly improved patient outcomes. These therapies offer hope for reduced steroid dependence and better long-term health for children with JIA.
Area of Science:
- Pediatric Rheumatology
- Immunology
- Pharmacology
Background:
- Juvenile idiopathic arthritis (JIA) management has evolved significantly over the past decade.
- Improvements are driven by more effective drug utilization and novel therapeutic discoveries.
Purpose of the Study:
- To review the current landscape of JIA management strategies.
- To highlight advancements in pharmacotherapy and emerging treatments.
Main Methods:
- Review of current literature on JIA treatment modalities.
- Analysis of the role of conventional disease-modifying antirheumatic drugs (DMARDs) and biological agents.
- Discussion of corticosteroid use and novel interventions like stem cell transplantation.
Main Results:
- Methotrexate remains a cornerstone for moderate to severe polyarticular JIA.
- Biologic agents, particularly anti-TNF therapies, are increasingly used for refractory cases.
- Judicious corticosteroid use and intra-articular injections are emphasized.
- Autologous stem cell transplantation shows promise for severe, refractory JIA.
Conclusions:
- Modern JIA management offers substantial benefits, improving patient prognosis.
- A shift towards targeted therapies and conservative corticosteroid use is evident.
- Multidisciplinary care remains crucial for holistic child well-being.